In a systematic analysis of post-CD19 CAR-T cell therapy, the frequencies of anemia, thrombocytopenia, and neutropenia of all grades were reported as 65%, 55%, and 78%, respectively. This evidence concerns the gene CD19 and Thrombocytopenia.